WO2006126630A1 - ドリペネムの水溶液の製造方法 - Google Patents
ドリペネムの水溶液の製造方法 Download PDFInfo
- Publication number
- WO2006126630A1 WO2006126630A1 PCT/JP2006/310437 JP2006310437W WO2006126630A1 WO 2006126630 A1 WO2006126630 A1 WO 2006126630A1 JP 2006310437 W JP2006310437 W JP 2006310437W WO 2006126630 A1 WO2006126630 A1 WO 2006126630A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- doripenem
- flow
- aqueous solution
- suspension
- heating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
Definitions
- the present invention relates to a method for producing an aqueous solution of doripenem. More specifically, the present invention relates to a method for producing an aqueous solution of doripenem, characterized in that an aqueous suspension of doripenem is dissolved by heating in a flow system.
- the distribution-type heating method is a heating method in which the majority is placed in a cooling environment, only the required amount is heated and melted to the target temperature, repeated in order, and finally the heat-dissolved material is collected.
- the batch heating method is a heating method that continues to receive a heat load until the entire temperature reaches the target temperature.
- the amount of decomposition is affected by temperature and the time of exposure to the temperature environment.
- the entire slurry is subjected to a heat load, and the decomposition of the compound proceeds until reaching the target temperature and dissolving.
- the entire slurry should be placed in a cooling environment. Prevents decomposition of the compound, and quickly raises and dissolves the slurry little by little, and quickly cools and crystallizes the slurry, thereby minimizing decomposition of the compound. If the whole slurry is heated and dissolved by batch method, the time required to reach the target temperature is, for example, about 1 of 20 minutes, although it depends on the scale, compared to the case of increasing temperature by flow method. It becomes possible to.
- a flow-type heating and dissolving machine that can heat a solution by a flow-type heating method is commercially available, and it is also possible to use one.
- Patent Document 2 as a method for sterilizing a pharmaceutical composition containing a suspension of a pharmaceutical, a step of rapidly heating the pharmaceutical composition from ambient temperature to high temperature, the pharmaceutical composition is heated to the high temperature or higher.
- a method comprising the steps of maintaining a temperature for a period of time and rapidly cooling the pharmaceutical composition to ambient temperature.
- Patent Document 1 Patent No. 2, 542, 773
- Patent Document 2 Special Table 2004— 513749
- the present inventor has found that doripenem is unstable to heat. Therefore, it is important to prevent the degradation of doripenem when producing an aqueous solution of doripenem. That is, a method for producing an aqueous solution of doripenem while preventing decomposition of doripenem by heat has been demanded.
- the present inventor has found the following invention as a method for producing an aqueous solution of doripenem while preventing decomposition of doripenem by heat.
- the water suspension of doripenem is circulated for 4 to 8 LZ through a flow-type heating and dissolving machine with an inner diameter of 20 to 26 mm and a length of 25 to 30 m having a heating source of 50 to 70 ° C.
- a step of producing an aqueous solution of doripenem by any one of the above methods (1) to (3), and crystallizing doripenem dihydrate from the aqueous solution, and the dihydrate A method for producing doripenem monohydrate, comprising a step of drying the crystals,
- a method for producing an aqueous solution of doripenem characterized by continuously heating an aqueous suspension of doripenem;
- the present invention is a method for producing an aqueous solution of doripenem, characterized in that an aqueous suspension of doripenem is heated and dissolved with a flow-type heating and dissolving machine.
- Drivenem is a compound having the following structure described in Patent No. 2,542,773, known as an antibacterial agent.
- the chemical name is (+)-(4R, 5S, 6S) -6-[(lR) -l-hydroxyethyl] -4-methyl-7-oxo-3-[[(3S, 5S) -5- Sulfamoylaminomethyl) pyrrolidine-3-yl] thio] -1-azabicyclo [3.2.0] hept-2-en-2-carboxylic acid).
- Aqueous suspension of dripenem means a liquid in which dripenem is suspended in water, for example, a water suspension in which 50 to 60 g of dripenem is mixed per liter of water. To do.
- the aqueous suspension of doripenem used in the present invention is preferably stored at room temperature (about 15 to 25 ° C.) or less in order to suppress the decomposition of doripenem. For example, cooling to 10 ° C or less is preferable.
- the present invention is suitable for producing a large amount of an aqueous solution of doripenem from a large amount of an aqueous suspension of doripenem. For example, a 200 to 500 L aqueous suspension is used.
- the aqueous suspension may contain an organic solvent other than water as long as the doripenem is suspended. In this case, the finally obtained aqueous solution of doripenem may also contain an organic solvent other than water.
- Heat-dissolving with a flow-type heat dissolver means that a large amount of water suspension is not heated at a time. This means that the suspension is heated with a flow-type heating and dissolving machine, and the doripenem is dissolved in order, and immediately after dissolution, the aqueous solution of the doripenem is discharged from the flow-type heating and dissolving machine. By continuously heating and recovering and cooling the aqueous solution, it is possible to suppress the decomposition of the doripenem and efficiently produce the aqueous solution of doripenem.
- a drupenem aqueous suspension is stored in a container and stored in a low-temperature environment where decomposition can be suppressed.
- a flow-type heating and dissolving machine By heating the supplied suspension of doripenem in a flow-type heating and dissolving machine, dissolving the doripenem, and continuously discharging the aqueous solution of doripenem with the flow-type heating and dissolving machine, An aqueous solution of dribenem can be produced.
- the temperature for melting by heating is preferably 50 to 70 ° C, particularly 50 to 60 ° C, and more preferably 50 to 55 ° C.
- the residence time of the aqueous suspension in the flow-type heating and dissolving machine is preferably 130 to 160 seconds. Note that the optimum residence time varies depending on the heating temperature.
- a commercially available heat-dissolving machine can be used.
- a flow-type heating and dissolving machine By using a flow-type heating and dissolving machine, an aqueous solution of doripenem can be produced while avoiding excessive heating that causes unacceptable decomposition of the doripenem. That is, by using a flow-type heating and dissolving machine, it is possible to suppress the decomposition of the doripenem by heating the doripenem in a short time at a high temperature.
- the container that holds the water suspension of dripenem is stainless steel. It is made of stainless steel and can accommodate a volume of 280L, for example. Alternatively, a reaction vessel that can accommodate the same volume may be used.
- the container may have a temperature control function in order to suppress the decomposition of doripenem in the water suspension.
- the flow-type heat dissolver is preferably a flow-type heat dissolver having an inner diameter of 20 to 26 mm (for example, 25 mm) and a length of 25 to 30 m (for example, 28 m).
- a flow-type heating and melting machine such as stainless steel can be used.
- the recovery device for recovering the aqueous solution of doripenem is made of stainless steel or the like, and can accommodate, for example, a volume of 280L.
- dripenem can be crystallized in the collector.
- the collector may have a temperature control function in order to suppress the decomposition of doripenem in the aqueous solution.
- the supply of the water suspension of doripenem to the flow-type heat-dissolving machine can be carried out by pressurized pressure feeding or a pump.
- the flow rate may be about 4 to 8 LZ (for example, 6 LZ).
- a dripenem aqueous suspension container is installed at the top of the flow-type heating dissolver, and a dripenem aqueous solution collector is installed at the bottom of the flow-type heat-dissolving device.
- the water suspension can be supplied to the flow-type heating and dissolving machine by natural dropping. The drop speed at this time should be about the same as when using a pressurized pump or a pump.
- an aqueous solution of doripenem is produced by the above-described method, and further, doripenem dihydrate is crystallized from the obtained aqueous solution of doripenem, and the dihydrate crystals are dried (for example, And a method of producing doripenem monohydrate, which includes a step of drying under reduced pressure at 50 ° C.). Crystallization is performed at room temperature or under cooling. Before crystallization, use a filter to filter the aqueous solution of doripenem. Crystallization of doripenem dihydrate from an aqueous solution of doripenem and production of doripenem monohydrate by drying the dihydrate crystal (for example, drying under reduced pressure at 50 ° C). It is disclosed in WO01 / 072750!
- the present invention also includes a method for producing an aqueous solution of doripenem, characterized by continuously heating an aqueous suspension of doripenem.
- This method means a method of producing an aqueous solution of doripenem by superheating a water suspension of doripenem by a flow-type heating method that is not a batch heating method.
- the aqueous suspension of doribenem is continuously heated by heating using a flow-type heating dissolver to produce an aqueous solution of doripenem.
- Force This method is not particularly limited to those using a flow-type heating dissolver as long as it is based on a flow-type heating method.
- a suspension of doripenem (a suspension of 15.5 kg of doripenem in 280 L of water) was cooled to 10 ° C or less to suppress decomposition during standby.
- This aqueous suspension is circulated in a flow-type heating and melting machine with a heating source of about 60 ° C and an inner diameter of about 23 mm and a length of about 28 m for about 6 LZ.
- a doripenem aqueous solution at about 55 ° C was obtained at the outlet of the dissolver.
- the resolution of doripenem at 28m in the flow-type heating and dissolving machine was about 0.2%.
- Figure 1 shows the residual rate of doripenem at each position of the flow-type heating and dissolving machine.
- Dripenem aqueous suspension (water suspension of 15.5 kg of doripenem mixed with 280 L of water) was cooled to 10 ° C or less to suppress decomposition during standby. This aqueous suspension was dissolved as it was using a heating medium at about 60 ° C to obtain an aqueous solution of doripenem at about 55 ° C. The degree of degradation of doripenem measured immediately after the dissolution of doripenem was about 7%.
- Figure 5 shows the remaining rate of dripenem in a batch system.
- FIG. 1 shows the residual rate of doripenem at each position of a flow-type heating and dissolving machine.
- FIG. 5 Shows the survival rate of doripenem in a batch system.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007517890A JP4149506B2 (ja) | 2005-05-26 | 2006-05-25 | ドリペネムの水溶液の製造方法 |
CN200680018085XA CN101180051B (zh) | 2005-05-26 | 2006-05-25 | 多利培南水溶液的制备方法 |
EP06756587.9A EP1886682B1 (en) | 2005-05-26 | 2006-05-25 | Method for preparation of aqueous doripenem solution |
US11/920,998 US8093284B2 (en) | 2005-05-26 | 2006-05-25 | Process for producing aqueous solution of doripenem |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005153704 | 2005-05-26 | ||
JP2005-153704 | 2005-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006126630A1 true WO2006126630A1 (ja) | 2006-11-30 |
Family
ID=37452054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/310437 WO2006126630A1 (ja) | 2005-05-26 | 2006-05-25 | ドリペネムの水溶液の製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8093284B2 (ja) |
EP (1) | EP1886682B1 (ja) |
JP (1) | JP4149506B2 (ja) |
KR (1) | KR100946075B1 (ja) |
CN (1) | CN101180051B (ja) |
TW (1) | TWI353855B (ja) |
WO (1) | WO2006126630A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017513916A (ja) * | 2014-04-28 | 2017-06-01 | ジェイダブリュ ファーマセウティカル コーポレーション | ドリペネムの新規な結晶およびその製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2276762B1 (en) * | 2008-03-24 | 2014-10-01 | Ranbaxy Laboratories Limited | Process for the preparation of sterile doripenem |
CN102233278B (zh) * | 2010-04-29 | 2013-11-06 | 湖北益泰药业有限公司 | 培南类药物生产中回收铑催化剂的方法 |
CN105061284B (zh) * | 2015-08-18 | 2017-12-29 | 齐鲁安替(临邑)制药有限公司 | 一种碳青霉烯类抗生素的开环杂质的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2542773B2 (ja) | 1991-08-20 | 1996-10-09 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体 |
WO2001072750A1 (fr) | 2000-03-31 | 2001-10-04 | Shionogi & Co., Ltd. | Nouvelle forme cristalline d'un derive de pyrrolidylthiocarbapenem |
JP2004513749A (ja) | 2000-11-24 | 2004-05-13 | ブレス リミテッド | 薬剤の滅菌 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3150006A (en) * | 1962-06-11 | 1964-09-22 | Corn Products Co | System for continuously dissolving dextrose |
PT758651E (pt) * | 1994-05-02 | 2002-12-31 | Shionogi & Co | Cristal de derivado de pirrolidiltiocarbapenem formulacao liofilizada contendo o citado cristal e processo para a producao do mesmo |
-
2006
- 2006-05-24 TW TW095118350A patent/TWI353855B/zh not_active IP Right Cessation
- 2006-05-25 EP EP06756587.9A patent/EP1886682B1/en active Active
- 2006-05-25 KR KR1020077030135A patent/KR100946075B1/ko not_active IP Right Cessation
- 2006-05-25 JP JP2007517890A patent/JP4149506B2/ja active Active
- 2006-05-25 WO PCT/JP2006/310437 patent/WO2006126630A1/ja active Application Filing
- 2006-05-25 US US11/920,998 patent/US8093284B2/en not_active Expired - Fee Related
- 2006-05-25 CN CN200680018085XA patent/CN101180051B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2542773B2 (ja) | 1991-08-20 | 1996-10-09 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体 |
WO2001072750A1 (fr) | 2000-03-31 | 2001-10-04 | Shionogi & Co., Ltd. | Nouvelle forme cristalline d'un derive de pyrrolidylthiocarbapenem |
JP2004513749A (ja) | 2000-11-24 | 2004-05-13 | ブレス リミテッド | 薬剤の滅菌 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1886682A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017513916A (ja) * | 2014-04-28 | 2017-06-01 | ジェイダブリュ ファーマセウティカル コーポレーション | ドリペネムの新規な結晶およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1886682B1 (en) | 2015-03-04 |
US20090264493A1 (en) | 2009-10-22 |
CN101180051B (zh) | 2010-09-08 |
JP4149506B2 (ja) | 2008-09-10 |
TWI353855B (en) | 2011-12-11 |
CN101180051A (zh) | 2008-05-14 |
EP1886682A1 (en) | 2008-02-13 |
KR20080012994A (ko) | 2008-02-12 |
US8093284B2 (en) | 2012-01-10 |
JPWO2006126630A1 (ja) | 2008-12-25 |
TW200706181A (en) | 2007-02-16 |
EP1886682A4 (en) | 2012-01-18 |
KR100946075B1 (ko) | 2010-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2572147A1 (en) | Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | |
WO2006126630A1 (ja) | ドリペネムの水溶液の製造方法 | |
JP2003286287A (ja) | 塩酸エピナスチン高融点型結晶の製造法 | |
CN108329205A (zh) | 双(2-乙酰氧基苯甲酸)钙脲化合物的制备方法 | |
CN104530084B (zh) | 一种头孢呋辛钠的新晶型及其结晶制备方法 | |
JP2011020950A (ja) | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 | |
CN103167872B (zh) | 用于生产l-肉碱酒石酸盐的方法 | |
WO2011001887A1 (ja) | アクリル酸の晶析装置およびこれを用いたアクリル酸の晶析方法 | |
CN107188798A (zh) | 一种可控制粒度的枸橼酸钠的精制工艺及实现装置 | |
NO337279B1 (no) | Ny krystallinsk form av 8-cyano-1-cyklopropyl-7-((1S,6S)-2,8-diazabicyklo[4.3 0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-okso-3-quinolinkarboksylsyre, medikamenter som inneholder denne, og anvendelse derav. | |
JP4438077B2 (ja) | 電子材料洗浄用ガス溶解水の調製方法 | |
JP6517996B2 (ja) | P1,p4−ビス(5’−ウリジル)テトラホスフェート結晶の保管方法 | |
JP6711709B2 (ja) | エゼチミブの製造方法 | |
JP2006305450A (ja) | ステロール類の晶析方法およびそのシステム | |
KR101542344B1 (ko) | 이온성 액체를 이용한 유기재료 정제 방법 및 장치 | |
CA2523854C (en) | Crystals of quinolinecarboxylic acid derivative solvate | |
JP2006156920A (ja) | 洗浄液の結晶化再生装置 | |
JP2016064988A (ja) | 1‐(3‐ベンゾイルオキシプロピル)‐7‐シアノ‐5‐[(2r)‐2‐({2‐[2‐(2,2,2‐トリフルオロエトキシ)フェノキシ]エチル}アミノ)プロピル]インドリンの酒石酸塩を製造する方法 | |
O’Malley | Crystal Growth and Design of Multicomponent Pharmaceuticals | |
JP4774192B2 (ja) | 1,2−ジクロロエタンを含まないゾニサミドの結晶の製造方法およびゾニサミドの高純度結晶 | |
JP5914246B2 (ja) | ブリンゾラミドの精製方法 | |
CN106674272A (zh) | 一种用于氨磷汀的加工方法 | |
TW201805272A (zh) | 製備白克列(Boscalid)之方法 | |
JP2005533099A (ja) | 化合物の水和物混合物を制御する方法 | |
JPS6072857A (ja) | 高純度s−カルボキシメチル−l−システイン塩酸塩の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680018085.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007517890 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11920998 Country of ref document: US Ref document number: 5350/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006756587 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077030135 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006756587 Country of ref document: EP |